News VALBIOTIS

Equities

ALVAL

FR0013254851

Real-time Euronext Paris Other stock markets 14:22:12 29/04/2024 BST			5-day change	1st Jan Change
3.89 ^EUR	-0.26%		+0.39%	-22.20%

04-26	Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-03	Valbiotis: launch of Valbiotis PRO Cholesterol in May	CF

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2023	04-26	CI
Valbiotis publishes its annual accounts 2023	04-26	EQ
Valbiotis: launch of Valbiotis PRO Cholesterol in May	04-03	CF
Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May	04-03	EQ
Valbiotis presents its 2024 financial communication calendar	01-29	EQ
Valbiotis sets out its commercial and clinical roadmap for 2024	01-16	EQ
Valbiotis: capital increase successfully completed	12-22	CF
Valbiotis announces the success of its €15 M capital increase	12-22	EQ
Valbiotis: 15 ME capital increase	12-12	CF
Valbiotis' Plant Extract Receives New Dietary Ingredient Status from US FDA	12-12	MT
Valbiotis announces the launch of a capital increase	12-11	EQ
Valbiotis announces the availability of an amendment to the Universal Registration Document	12-11	EQ
Valbiotis announces that it has received Food and Drug Administration (FDA) approval for New Dietary Ingredient (NDI) status	12-11	EQ
VALBIOTIS SA:	12-04	EQ
Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes	11-07	EQ
VALBIOTIS : Rapport financier semestriel 2023	15/10/23	PU
VALBIOTIS SA: the Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for diabetes	02/10/23	EQ
Valbiotis SA Reports Earnings Results for the Half Year Ended June 30, 2023	28/09/23	CI
Valbiotis publishes its financial report for the first half of 2023 and confirms its strategic roadmap	28/09/23	EQ
Valbiotis presents the full results of the Phase II/III REVERSE-IT study, impressive efficacy of TOTUM 63 against prediabetes and the early stages of type 2 Diabetes, a first for a non-drug active substance	12/09/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News VALBIOTIS

Equities

ALVAL

FR0013254851

Summary

Filters